Data / Form D filings / Arialys Therapeutics, Inc.
Arialys Therapeutics, Inc.: Form D filings
Arialys Therapeutics, Inc., a biotechnology company in La Jolla, CA, filed 2 Form D notices with the SEC between 2022 and 2025. The latest, on July 1, 2025, reports $14.8 million sold of a $24.8 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 11099 NORTH TORREY PINES ROAD, SUITE 290, La Jolla, CA, 92037
- Phone
- (858) 750-4700
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1956823
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | New notice | $24,800,006 | $14,800,017 | $9,999,989 | 7 | Jun 13, 2025 | sec.gov |
| Dec 2, 2022 | New notice | $55,000,000 | $14,333,337 | $40,666,663 | 6 | Nov 18, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jay Lichter, Ph.D. | Director | |
| Peter Flynn, Ph.D. | Executive Officer, Director | |
| Brian Slingsby, M.D., Ph.D., M.P.H. | Director | |
| Ed Hurwitz | Director | |
| Ashish Xavier, Ph.D. | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jun 30, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Arialys Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.